- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Unicycive Therapeutics Inc (UNCY)
Unicycive Therapeutics Inc stock price live, this page displays NASDAQ UNCY stock exchange data. View the UNCY premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Unicycive Therapeutics Inc real time stock price chart below.
What Is the Unicycive Therapeutics Inc Stock Price Today?
The Unicycive Therapeutics Inc stock price today is 4.420.
What Is the Stock Symbol for Unicycive Therapeutics Inc?
The stock symbol for Unicycive Therapeutics Inc is ""UNCY.""
What Stock Exchange Does Unicycive Therapeutics Inc Trade On?
Unicycive Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Unicycive Therapeutics Inc a Good Stock to Buy?
Determining whether Unicycive Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the UNCY quote. (ISIN: US90466Y2028)
What Is the Unicycive Therapeutics Inc Stock Price Today?
The Unicycive Therapeutics Inc stock price today is 4.420.
What Is the Stock Symbol for Unicycive Therapeutics Inc?
The stock symbol for Unicycive Therapeutics Inc is ""UNCY.""
What Stock Exchange Does Unicycive Therapeutics Inc Trade On?
Unicycive Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Unicycive Therapeutics Inc a Good Stock to Buy?
Determining whether Unicycive Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the UNCY quote. (ISIN: US90466Y2028)
NASDAQ
Currency in USD
4.420
-0.290(-6.16%)
Closed·
After Hours
4.520+0.100(+2.26%)
·
Fair Value
An estimate of a Unicycive Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.415
4.721
52 wk Range
2.020
11.000
UNCY Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
UNCY is not included in our AI-picked strategies. See which stocks are.
Review Strategies
Fair Value
An estimate of a Unicycive Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.4154.721
52 wk Range
2.02011.000
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
UNCY Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Unicycive Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
63.125
Upside
+1,328.17%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
2 analysts have revised their earnings upwards for the upcoming period
- Form 8K Unicycive Therapeutics Inc For: 30 June
- Investing.com
- Form 8K Unicycive Therapeutics Inc For: 8 July
- Investing.com
- Form 8K Unicycive Therapeutics Inc For: 8 July
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Unicycive Therapeutics Inc Company Profile
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb RZB 012 for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company also evaluates licensing of technologies and drugs for orphan diseases, other renal, liver, and other metabolic diseases affecting fibrosis and inflammation. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd to develop and commercialize oxylanthanum carbonate; Sphaera Pharma Pte. Ltd.; Syneos Health LLC to develop of UNI-494; Inotiv for preclinical trial and related services for oxylanthanum carbonate and UNI-494; Lee’s Pharmaceutical (HK) Limited; and Lotus International Pte Ltd for the development, registration filing, and approval for oxylanthanum carbonate. The company was incorporated in 2016 and is based in Los Altos, California.
Unicycive Therapeutics Inc SWOT Analysis
Kidney Disease Focus | Unicycive Therapeutics develops novel treatments for chronic kidney disease, with lead product OLC in pivotal Phase 2 study for hyperphosphatemia |
Market Potential | Explore the significant opportunity in the hyperphosphatemia market, with over 500,000 kidney dialysis patients potentially benefiting from OLC |
Financial Outlook | Analyst price targets range from $3 to $9, with a strong cash position of $48.9 million providing runway into 2026 despite projected near-term losses |
Regulatory Tailwinds | Learn how recent CMS payment decisions create a favorable environment for OLC's potential market entry, aligning with its expected 2025 launch |
Compare UNCY to Peers and Sector
Metrics to compare | UNCY | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipUNCYPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.5x | −4.4x | −0.5x | |
PEG Ratio | −0.04 | 0.02 | 0.00 | |
Price/Book | 5.0x | 3.1x | 2.6x | |
Price / LTM Sales | - | 9.9x | 3.2x | |
Upside (Analyst Target) | - | 185.0% | 42.0% | |
Fair Value Upside | Unlock | 8.8% | 6.6% | Unlock |
Analyst Ratings
8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 63.125
(+1,328.17% Upside)
Earnings
Latest Release
May 14, 2025
EPS / Forecast
-0.61 / -0.10
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Stock Exchange Does Unicycive Therapeutics Trade On?
Unicycive Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Unicycive Therapeutics?
The stock symbol for Unicycive Therapeutics is "UNCY."
What Is the Unicycive Therapeutics Market Cap?
As of today, Unicycive Therapeutics market cap is 55.87M.
What Is Unicycive Therapeutics's Earnings Per Share (TTM)?
The Unicycive Therapeutics EPS (TTM) is -1.85.
When Is the Next Unicycive Therapeutics Earnings Date?
Unicycive Therapeutics will release its next earnings report on 17 Aug 2025.
From a Technical Analysis Perspective, Is UNCY a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Unicycive Therapeutics Stock Split?
Unicycive Therapeutics has split 1 times.
How Many Employees Does Unicycive Therapeutics Have?
Unicycive Therapeutics has 23 employees.
What is the current trading status of Unicycive Therapeutics (UNCY)?
As of 30 Jul 2025, Unicycive Therapeutics (UNCY) is trading at a price of 4.42, with a previous close of 4.42. The stock has fluctuated within a day range of 4.42 to 4.72, while its 52-week range spans from 2.02 to 11.00.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.